Overview: JC Virus IgM TestIntroduction: The JC Virus IgM Test tests for JC virus IgM antibodies to diagnose recent infection, linked to neurological issues in immunocompromised patients, aiding in early diagnosis. Affecting 1 in 100,000 immunocompromised individuals, recent JC infection poses diagnostic challenges due to latency. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses ELISA for high sensitivity, supporting virology screening. This test is vital for diagnosis, early intervention, and improving outcomes in neurology.
Other Names: JC Virus IgM Antibody Test, Recent PML Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: JC virus serology began in the 1990s with research by Knowles, who developed antibody detection. ELISA advancements in the 2000s by Thermo Fisher improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects JC virus IgM antibodies to diagnose recent infection, guides preventive care, and evaluates patients with neurological symptoms, aiming to manage disease.
Test Parameters: JC virus IgM levels
Pretest Condition: No special preparation required. Collect serum. Report history of recent symptoms.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological symptoms or immunosuppression. Include current medications or HIV status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., PML), and sample collection risks.
Procedural Considerations: Uses ELISA to measure IgM, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive IgM suggests recent infection, guiding care. Early intervention might prevent PML, while untreated cases lead to complications. Negative results may require PCR.
Specialist Consultation: Consult a neurologist or infectious disease specialist for interpretation.
Additional Supporting Tests: JC virus PCR, MRI, or immune status to confirm diagnosis.
Test Limitations: Indicates recent infection only; correlation with symptoms needed. False positives possible with cross-reactivity.
References: CDC Guidelines, 2023; Journal of Clinical Microbiology, Knowles WA, 2022.
